Drug Oncology

Brukinsa

Payments companies reported to CMS as associated with Brukinsa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$8.2Massociated payments (2023-2025)

10,076clinicians with associated payments

6companies reporting

By year

2023 $3.1M

2024 $2.8M

2025 $2.3M

Payments reported as associated with Brukinsa, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $4.5M

Medical Oncology $1.5M

Hematology (Internal Medicine) $994K

Nurse Practitioner $227K

Family $216K

Internal Medicine $105K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Brukinsa

These are the largest totals companies reported as associated with Brukinsa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Andrew Whiteley	Dallas, TX	Medical Oncology	$243,431.17
Catherine Coombs	Orange, CA	Hematology & Oncology	$230,212.27
Ryan Jacobs	Charlotte, NC	Hematology (Internal Medicine)	$212,840.71
Hakan Kaya	Spokane, WA	Medical Oncology	$203,783.49
Moshe Levy	Dallas, TX	Medical Oncology	$197,174.00
John Renshaw	San Antonio, TX	Hematology & Oncology	$190,716.41
Imadeddine Tabbara	Washington, DC	Hematology & Oncology	$177,112.37
Mohamed Hegazi	Louisville, KY	Hematology & Oncology	$147,786.12
Nakhle Saba	Baton Rouge, LA	Hematology & Oncology	$142,044.86
Daniel Efiom-Ekaha	York, PA	Hematology & Oncology	$137,370.01

Prescribed Brukinsa?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.